Kezar Life Sciences, Inc. (NASDAQ:KZR) to Post Q4 2023 Earnings of ($0.38) Per Share, William Blair Forecasts

Kezar Life Sciences, Inc. (NASDAQ:KZR) – Analysts at William Blair decreased their Q4 2023 earnings per share (EPS) estimates for shares of Kezar Life Sciences in a research report issued on Tuesday, November 14th. William Blair analyst M. Phipps now anticipates that the company will post earnings per share of ($0.38) for the quarter, down from their prior estimate of ($0.36). The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($1.37) per share. William Blair also issued estimates for Kezar Life Sciences’ Q1 2024 earnings at ($0.28) EPS, Q2 2024 earnings at ($0.26) EPS, Q3 2024 earnings at ($0.26) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.07) EPS, FY2025 earnings at ($1.03) EPS, FY2026 earnings at ($1.11) EPS and FY2027 earnings at ($1.20) EPS.

Several other brokerages have also issued reports on KZR. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Kezar Life Sciences in a research report on Thursday, October 12th. Wells Fargo & Company decreased their price objective on Kezar Life Sciences from $4.00 to $2.00 and set an “equal weight” rating for the company in a report on Tuesday. Finally, Jonestrading restated a “hold” rating on shares of Kezar Life Sciences in a report on Thursday, October 5th.

Kezar Life Sciences Price Performance

KZR stock opened at $0.79 on Thursday. The firm has a 50-day moving average of $0.99 and a 200 day moving average of $1.85. The company has a debt-to-equity ratio of 0.04, a current ratio of 17.73 and a quick ratio of 17.73. The company has a market cap of $57.55 million, a P/E ratio of -0.65 and a beta of 0.38. Kezar Life Sciences has a 1 year low of $0.67 and a 1 year high of $8.06.

Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.04. The company had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $0.50 million.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Pale Fire Capital SE bought a new stake in Kezar Life Sciences during the 3rd quarter valued at about $82,000. Acadian Asset Management LLC boosted its stake in shares of Kezar Life Sciences by 179.2% in the 3rd quarter. Acadian Asset Management LLC now owns 831,693 shares of the company’s stock worth $988,000 after buying an additional 533,760 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Kezar Life Sciences by 85.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 345,440 shares of the company’s stock worth $411,000 after purchasing an additional 159,571 shares during the last quarter. SG Americas Securities LLC bought a new stake in Kezar Life Sciences during the third quarter valued at approximately $39,000. Finally, RVW Wealth LLC purchased a new stake in shares of Kezar Life Sciences in the 3rd quarter worth $28,000. Hedge funds and other institutional investors own 86.83% of the company’s stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.